1. Home
  2. EBON vs TVRD Comparison

EBON vs TVRD Comparison

Compare EBON & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ebang International Holdings Inc.

EBON

Ebang International Holdings Inc.

HOLD

Current Price

$1.65

Market Cap

16.0M

Sector

Technology

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$1.09

Market Cap

15.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EBON
TVRD
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0M
15.7M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
EBON
TVRD
Price
$1.65
$1.09
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $8.88
AVG Volume (30 Days)
8.5K
★ 207.0K
Earning Date
08-14-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.01
EPS
★ N/A
N/A
Revenue
N/A
★ $911,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 959.30
52 Week Low
$1.35
$0.77
52 Week High
$3.89
$5.69

Technical Indicators

Market Signals
Indicator
EBON
TVRD
Relative Strength Index (RSI) 45.18 50.87
Support Level $1.35 $0.85
Resistance Level $2.34 $2.02
Average True Range (ATR) 0.17 0.17
MACD -0.01 0.05
Stochastic Oscillator 48.57 41.46

Price Performance

Historical Comparison
EBON
TVRD

About EBON Ebang International Holdings Inc.

Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: